Research Analysts Issue Forecasts for ResMed Q2 Earnings

ResMed Inc. (NYSE:RMD) – Stock analysts at William Blair lowered their Q2 2026 earnings per share (EPS) estimates for ResMed in a report released on Friday, October 31st. William Blair analyst B. Vazquez now expects that the medical equipment provider will earn $2.66 per share for the quarter, down from their previous estimate of $2.67. William Blair has a “Strong-Buy” rating on the stock. The consensus estimate for ResMed’s current full-year earnings is $9.47 per share. William Blair also issued estimates for ResMed’s Q3 2026 earnings at $2.74 EPS, Q4 2026 earnings at $2.84 EPS, FY2026 earnings at $10.80 EPS, Q1 2027 earnings at $2.84 EPS, Q2 2027 earnings at $2.93 EPS, Q3 2027 earnings at $3.04 EPS and FY2027 earnings at $12.00 EPS.

ResMed (NYSE:RMD) last posted its quarterly earnings data on Thursday, October 30th. The medical equipment provider reported $2.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.49 by $0.06. The business had revenue of $1.34 billion during the quarter, compared to the consensus estimate of $1.33 billion. ResMed had a return on equity of 25.62% and a net margin of 27.22%.ResMed’s quarterly revenue was up 9.1% on a year-over-year basis. During the same period last year, the company earned $2.20 earnings per share.

Several other research analysts also recently commented on the company. Morgan Stanley set a $305.00 target price on ResMed in a research note on Friday. Mizuho cut their target price on ResMed from $310.00 to $300.00 and set an “outperform” rating for the company in a research report on Friday. Robert W. Baird cut their target price on ResMed from $320.00 to $300.00 and set an “outperform” rating for the company in a research report on Monday. Royal Bank Of Canada upped their target price on ResMed from $300.00 to $303.00 and gave the company an “outperform” rating in a research report on Friday. Finally, CLSA raised ResMed from a “hold” rating to an “outperform” rating in a report on Tuesday, September 2nd. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, ResMed presently has a consensus rating of “Moderate Buy” and an average target price of $297.45.

ResMed Stock Up 0.7%

RMD stock opened at $248.53 on Monday. The company has a quick ratio of 2.53, a current ratio of 3.44 and a debt-to-equity ratio of 0.11. The business has a 50 day moving average price of $271.04 and a two-hundred day moving average price of $261.68. The company has a market cap of $36.27 billion, a price-to-earnings ratio of 26.13, a P/E/G ratio of 1.75 and a beta of 0.83. ResMed has a twelve month low of $199.92 and a twelve month high of $293.81.

Institutional Trading of ResMed

Several hedge funds have recently made changes to their positions in RMD. SJS Investment Consulting Inc. boosted its holdings in shares of ResMed by 1,433.3% in the 3rd quarter. SJS Investment Consulting Inc. now owns 92 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 86 shares in the last quarter. WFA of San Diego LLC purchased a new position in shares of ResMed during the 2nd quarter worth approximately $26,000. GoalVest Advisory LLC purchased a new stake in shares of ResMed in the 3rd quarter worth approximately $37,000. Zions Bancorporation National Association UT purchased a new stake in shares of ResMed in the 1st quarter worth approximately $45,000. Finally, Groupe la Francaise purchased a new stake in ResMed during the 1st quarter valued at $45,000. 54.98% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director John Hernandez sold 2,575 shares of the firm’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $287.10, for a total transaction of $739,282.50. Following the completion of the sale, the director directly owned 4,045 shares of the company’s stock, valued at $1,161,319.50. This trade represents a 38.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Michael J. Farrell sold 8,009 shares of the stock in a transaction dated Tuesday, October 7th. The shares were sold at an average price of $282.85, for a total transaction of $2,265,345.65. Following the transaction, the chief executive officer owned 467,792 shares of the company’s stock, valued at approximately $132,314,967.20. The trade was a 1.68% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 18,693 shares of company stock worth $5,270,419 over the last 90 days. 0.65% of the stock is currently owned by corporate insiders.

ResMed Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 18th. Shareholders of record on Thursday, November 13th will be issued a $0.60 dividend. The ex-dividend date is Thursday, November 13th. This represents a $2.40 annualized dividend and a yield of 1.0%. ResMed’s dividend payout ratio is presently 24.56%.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.